Diamyd Medical AB Completes Screening for US Phase III Study

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Diamyd Medical (STO:DIAMB)(Pink Sheets:DMYDY) has completed the screening of patients for the US Phase III study, DiaPrevent, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age have already been enrolled in the study and have received their first injection of the antigen-based therapy Diamyd® or placebo.